TP53 (which encodes p53 protein) is the most frequently mutated gene among all human cancers. Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer. Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation. Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours. Cancer cell proliferation is markedly lowered by genetic knockdown of MLL1 or by pharmacological inhibition of the MLL1 methyltransferase complex. Our study reveals a novel chromatin mechanism underlying the progression of tumours with GOF p53, and suggests new possibilities for designing combinatorial chromatin-based therapies for treating individual cancers driven by prevalent GOF p53 mutations.
Most mutant forms of p53 are caused by single amino acid substitutions mapping to the DNA-binding domain 1 . These mutations result in expression of full-length p53 protein, but loss of wild-type (WT) tumour suppressive function [2] [3] [4] . The high prevalence of missense substitutions, particularly certain 'hotspot' mutations, suggests a selective advantage during cancer progression. Indeed, these mutants gain neomorphic oncogenic functions, including altered cancer spectrum 2,3 , deregulated metabolic pathways 4, 5 , increased metastasis 6, 7 and enhanced chemotherapy resistance 8 . Evidence from recent studies points to one potential mechanism of GOF p53, functioning through association with other transcription factors and driving gene transcription in oncogenic pathways, such as the mevalonate pathway 4 and etoposide-resistance pathway 8 . A transcriptional mechanism is further supported by the importance of retaining an intact transactivation domain for oncogenic GOF p53 function 4, 9 . Nevertheless, how GOF p53 contributes to major changes of the cancer genome and transcriptome remains to be elucidated 9, 10 . Altered chromatin pathways have been implicated in various aspects of cancer 11, 12 , given their regulation of genome-wide transcription programs 13, 14 . However, to our knowledge, to date there has not been evidence of direct crosstalk between GOF p53 mutants and chromatin regulation.
Genome-wide binding of GOF p53 mutants
We carried out chromatin immunoprecipitation followed by sequencing (ChIP-seq) to determine genome-wide binding locations of p53 in a panel of breast cancer cell lines: MCF7 (wild-type p53), MDA-MB-175VII (wild-type p53), HCC70 (p53(R248Q)), BT-549 (p53(R249S)), and MDA-MB-468 (p53(R273H)). We found that the binding of p53 to gene-proximal regions (less than 10 kilobases (kb)) of transcription start sites (TSS) in the two wild-type p53 cell lines strongly resembled each other, whereas these wild-type p53 peaks were highly dissimilar from the peaks in any of the GOF p53 mutants. Notably, p53 binding patterns in the three GOF p53 cell lines were similar when compared to each other ( Fig. 1a and Extended Data Fig. 1a ). In addition, we aligned published p53(R248W) ChIP-seq data from Li-Fraumeni syndrome (LFS) MDAH087 cells 8 , and again, TSS-proximal peaks of p53(R248W) resembled those of p53(R273H) and p53(R248Q) (Extended Data Fig. 1b, c ), but were distinct from the wild-type p53 peaks (Extended Data Fig. 1d, e) .
We performed motif analysis for TSS-proximal peaks of the p53(R273H) mutant that predicted the E26 transformation-specific (ETS) motif as the most enriched (Extended Data Fig. 2a ), which is distinct from the wild-type p53 motif (Extended Data Fig. 2b ). One ETS family member, ETS2, has been shown to consistently associate with mutant p53 (ref. 8) . We confirmed that ETS2 interacts with various GOF p53 mutants, but interacts to a much lesser extent with wild-type p53 (Fig. 1b and Extended Data Fig. 2c ), as previously noted 8 . Co-immunoprecipitation at endogenous protein levels also demonstrated that ETS2 interacts with GOF p53, but not with wildtype p53 (Extended Data Fig. 2d, e) . We analysed ChIP-seq data sets from the ENCODE project for all transcription factors 15, 16 , and observed that, compared to other transcription factors, ETS family proteins have significantly higher overlap with GOF p53 TSS-proximal peaks, but not with wild-type p53 TSS-proximal peaks (Extended Data  Fig. 2f, g ). Notably, in both wild-type and GOF p53 cases, RNA polymerase II (Pol II) group has the highest percentage overlap with p53 peaks, indicative of transcriptional activity. The extent of Pol II overlap is similar to the ETS group in GOF p53 cells, but much higher than the ETS group in wild-type p53 cells (Extended Data Fig. 2f, g ).
GOF p53 targets chromatin regulators
To determine specific functional categories, we performed gene ontology (GO) analysis on TSS-proximal peaks. As expected, DNA damage response pathways were most enriched in wild-type p53 targets (Extended Data Fig. 2h and Supplementary Table 1 ). In contrast, p53(R273H) bound to genes related to translation and ribosomal synthesis ( Fig. 1c and Supplementary Table 1) , which was reasonable given the rapid growth rate of these cells. We were particularly intrigued by GOF p53 binding to a group of genes functionally related to histone methylation (Fig. 1c) . This was seen in UCSC Genome Browser views at MLL1 (KMT2A) and MLL2 (KMT2D), genes encoding methyltransferases of histone H3 lysine 4 (H3K4) (Fig. 2a ) that are components of alternative forms of the COMPASS complex (complex proteins associated with Set1). The other two GOF p53 mutants that we examined, as well as p53(R248W) from LFS MDAH087 cells 8 , all showed similar binding at MLL1 and MLL2 (Extended Data  Fig. 3a, b , e, f). UCSC Genome Browser views confirmed binding of GOF p53 to a gene encoding a common subunit of COMPASS complexes, RBBP5 (Extended Data Fig. 3h ). In contrast, wild-type p53 did not appear to bind any of these genes, although as expected it bound promoter regions of its canonical targets, including CDKN1A (which encodes p21 protein), MDM2 and BBC3 (also known as PUMA) ( Fig. 2a and Extended Data Fig. 3c, i, j) . We then analysed a large set of 600 chromatin regulators for potential GOF p53 binding, and found an additional group of chromatin regulatory genes that showed peak enrichment (Supplementary Table 2 ). Of particular interest among these was MOZ (KAT6A), a histone acetyltransferase, and UCSC Genome Browser views confirmed the presence of GOF p53 but not wild-type p53 ( Fig. 2a and Extended Data Fig. 3d, g ).
Using ChIP-quantitative PCR (ChIP-qPCR), we validated the binding of GOF p53 to MLL1, MLL2, and MOZ genes, but not adjacently upstream or downstream of the peak regions ( Fig. 2b and Extended Data Fig. 4a-c) . Moreover, we confirmed GOF p53 binding to all other targets in the 'histone methylation' GO category (RBBP5, OGT and PPP1CC), and to a few additional chromatin factors (including SMARCD2 and DCAF10), in all three GOF p53 cell lines (Extended Data Fig. 4d-f) . We verified the ChIP-qPCR results with a second p53 polyclonal antibody, FL393 (Extended Data Fig. 4g ). In parallel experiments with both p53 antibodies, wild-type p53 showed binding to the CDKN1A and MDM2 canonical binding sites, but not to any of the GOF p53 targets tested ( Fig. 2c and Extended Data Fig. 4h ). We also examined a pancreatic cancer cell line, PANC-1 (p53(R273H)), and observed a similar binding pattern (Extended Data Fig. 4i ), suggesting a general phenomenon in various cancer types. Furthermore, the ChIP-qPCR signal of GOF p53 was attenuated upon p53 knockdown (Fig. 2d) . Knockdown of ETS2 also led to reduced binding of GOF p53 over MLL1 and MOZ, and to a lesser extent, over the MLL2 peak region (Fig. 2e) . To test the association of GOF p53 near Mll1 in a non-tumour background, we performed ChIP-qPCR in primary mouse embryonic fibroblasts (MEFs) with GOF p53 or wild-type p53, and consistently, mouse GOF p53 showed significant enrichment over the Mll1 promoter region (Fig. 2f) .
GOF p53 regulates MLL, MOZ, and histone modifications
To examine whether GOF p53 is required for expression of the chromatin regulators, we reduced GOF p53 levels in human cancer cells and found that the mRNA levels of MLL1, MLL2 and MOZ were also decreased ( Fig. 3a and Extended Data Fig. 5a ); whereas no change was detected when the level of wild-type p53 was reduced (Extended Data Fig. 5b ). Simply increasing wild-type p53 protein levels by stabilization mediated by the compound nutlin did not recapitulate activation of the chromatin regulators (Extended Data Fig. 5c, d ). MLL1 protein levels were also decreased in the GOF p53 knockdown (Fig. 3b) , but not by wild-type p53 knockdown (Extended Data Fig.  5e ), as was also observed for MOZ protein levels (Extended Data Table 3 . f, ChIP-qPCR showing p53 or IgG enrichment in MEFs bearing wild-type p53 or p53(R172H). Error bars represent mean 6 s.e.m.; n 5 3; two-tailed Student's t-test: *P , 0.05; **P , 0.01; ***P , 0.001. Fig. 5f ). Reduction of ETS2 levels led to decreased expression of MLL1 and MOZ, and to a lesser extent, MLL2 ( Fig. 3c and Extended Data Fig. 5g ), which was in accordance with the relative binding changes of GOF p53 to these genes ( Fig. 2e) . We verified the ETS2 knockdown result in another GOF p53 cell line, BT-549, and detected similarly decreased expression of MLL1 and MOZ, and to a lesser extent, MLL2 (Extended Data Fig. 5h , i). We performed Pol II ChIP-qPCR and observed concomitantly decreased Pol II occupancy specifically over MLL1, MLL2, and MOZ TSS regions upon ETS2 knockdown (Fig. 3d) .
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We examined the importance of another ETS family member, ETS1. By contrast, ETS1 knockdown had no effect on the expression of MLL1, MLL2 or MOZ (Extended Data Fig. 5j , k), nor did it alter GOF p53 or Pol II binding (Extended Data Fig. 5l , m). As ETS family proteins consist of 28 members
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, it is likely that additional ETS protein(s) other than ETS1 may be involved. Nevertheless, our observations are consistent with previous studies showing that ETS2, but not ETS1, is important in mediating GOF p53 function 8, 18 . The regulation of histone-modifying enzymes led to investigation of the cognate histone post-translational modifications (PTMs). We observed a global decrease in histone H3 lysine 9 acetylation (H3K9ac, catalysed by MOZ 19 ) in response to knockdown of GOF p53, whereas other histone acetylation marks did not show notable changes ( Fig. 3e and Extended Data Fig. 5n , o, p). The reduction of H3K9ac was also observed when the level of MOZ itself was decreased by short hairpin RNA (shRNA) (Extended Data Fig. 5q ). In contrast, H3K4 tri-methylation and H3K4 mono-methylation (H3K4me3 and H3K4me1, catalysed by MLL1 and MLL2, respectively 20 ) showed only a slight global reduction upon GOF p53 knockdown ( Fig. 3e and Extended Data Fig. 5n , o, p). This is reasonable, however, given that H3K4 is methylated by six members of the COMPASS complexes 20 , and previous studies showed that inhibiting or knocking one of them out did not substantially change global H3K4 methylation 21, 22 . We further validated the regulation of Mll1, Mll2, and Moz by GOF p53 in the knock-in MEFs. We found significantly higher expression of these genes in GOF p53 MEFs than in wild-type p53 MEFs or in MEFs derived from p53 (gene Trp53) knockout mice (p53 null MEFs) ( Fig. 3f and Extended Data Fig. 6a-c) . Furthermore, when GOF p53 was reduced, Mll1 expression was also lowered (Fig. 3g and Extended Data Fig. 6d) , and ectopically expressing GOF p53 in p53 null MEFs enhanced Mll1 expression (Extended Data Fig. 6e, f) . GOF p53 MEFs also showed higher global level of H3K9ac, and a slight elevation of H3K4me3, compared with wild-type p53 or p53 null MEFs (Fig. 3h and Extended Data Fig. 6g) . Notably, other histone modifications associated with active gene transcription, including H3K27ac and H3K36me3, remained at comparable levels (Fig. 3h) . In addition, H3K4me3 or H3K9ac did not change upon knockdown of wild-type p53 (Extended Data Fig. 6h ), even though cell growth was increased as expected (Extended Data Fig. 6i ). Together, these data suggest that changes in H3K4me3 and H3K9ac are specific to GOF p53 directly activating MLL1 and MOZ enzymes.
The modest global change in H3K4me3 in the presence of GOF p53 prompted investigation of local changes in H3K4 methylation. We performed RNA-seq and H3K4me3 ChIP-seq in MEFs with endogenous wild-type p53 or GOF p53. Compared with the genome-wide average, known MLL1 target genes 22 were more highly expressed and displayed higher H3K4me3 enrichment in GOF p53 MEFs (Extended Data Fig. 6j ). For example, we observed increased H3K4me3 level and RNA expression within the Hoxa gene cluster ( Fig. 3i and Extended Data Fig. 6k ), a well-studied target of MLL1 and commonly upregulated in leukaemia 23, 24 . Conversely, wild-type p53 targets, such as Cdkn1a, showed decreased RNA expression and TSS-associated H3K4me3 in GOF p53 MEFs (Extended Data Fig. 6l) . Notably, H3K4me3 enrichment at the TSS of genes in GOF p53 MEFs was slightly, but significantly higher at a genome-wide level than in wild-type p53 MEFs (Extended Data Fig. 6m) , consistent with the slight global increase of H3K4me3 (Fig. 3h) . We validated the H3K4me3 ChIP-seq and RNA-seq results by ChIP-qPCR and RTqPCR, respectively, observing significantly higher H3K4me3 enrichment in GOF p53 MEFs, and higher expression of Hox genes, than in wild-type p53 or p53 null MEFs (Fig. 3j and Extended Data Fig. 6n ).
MLL1 is essential for cancer phenotype of GOF p53
Previous studies have revealed that cells expressing GOF p53 rely on it for cell growth and survival 25, 26 . GOF p53 knockdown in cancer cells led to a strong decrease in cell proliferation (Extended Data Fig. 7a ). By contrast, lowering of wild-type p53 levels resulted in elevated
Relative mRNA levels (normalized to lamin a/c) 0 0.5
Pol II ChIP/input 0 0.5 Supplementary Fig. 1 . Error bars represent mean 6 s.e.m.; n 5 3; twotailed Student's t-test; *P , 0.05; **P , 0.01; ***P , 0.001. Figs 6i and 7b) . To investigate the function of GOF p53 driving chromatin regulators, we carried out the same time course, and found that the reduction of MLL1 or MLL2 in GOF p53 cancer cells led to a striking loss of cell growth (Extended Data Fig. 7c) , phenocopying the knockdown of GOF p53 itself. By contrast, knockdown of MLL1 or MLL2 had a minimal effect on wild-type p53 cancer cells (Extended Data Fig. 7d, e) .
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We addressed the importance of this pathway to tumour-relevant phenotypes, first by examining the ability of cancer cells to form colonies. Reduction of MLL1 led to a decreased colony formation ability of MDA-MB-468 cells (p53(R273H)) ( Fig. 4a and Extended Data Fig. 7f ), but had little effect on the colony formation efficiency of MCF7 cells (wild-type p53) (Fig. 4b and Extended Data Fig. 7g) . Similar results were observed in breast cancer cells BT-549 (p53(R249S)) and pancreatic cancer cells PANC-1 (p53(R273H)) (Extended Data Fig. 7h, i) . We further confirmed the tumour formation phenotype in anchorage-independent growth assays in soft agar, showing that decreasing MLL1 specifically reduced the growth and colony size of GOF p53 cancer cells, but not wild-type p53 cancer cells (Extended Data Fig. 7j, k) . We also investigated tumour growth on NOD-scid-gamma (NSG) immunodeficient mice. Knockdown of MLL1 led to strongly reduced tumour formation ability in GOF p53 cells, as compared to GOF p53 cells with a non-targeting scrambled control knockdown (Fig. 4c, e) . In contrast, MLL1 knockdown did not alter the tumour formation ability of wildtype p53 cancer cells (Fig. 4d, e) , again supporting a specific role for MLL1 in cancers with GOF p53, but not wild-type p53.
To further explore a critical role that these chromatin regulators may play in supporting growth of GOF p53 cells, and to rule out possible confounding factors in established cancer cell lines, we performed Mll1 knockdown in the primary MEFs with knock-in GOF p53. Consistently, MLL1 reduction resulted in decreased proliferation of GOF p53 MEFs (Extended Data Fig. 8a) . Importantly, re-expression of MLL1 in GOF p53 MEFs with p53 knockdown partially rescued the growth defects (Fig. 4f) ; partial rescue probably results from GOF p53 driving expression of multiple downstream targets, as described above. These results strongly indicate a direct role of MLL1, functioning downstream of GOF p53 in maintaining proliferation of GOF p53 cells. We also performed MLL1 knockdown (Extended Data Fig. 8b ) in human non-cancer LFS cells-MDAH087 (p53(R248W)) and MDAH041 (p53 null 27 ; Extended Data Fig. 8c ). Similar to the results obtained in cancer cells and in MEFs, MLL1 knockdown reduced the growth rate of GOF p53 LFS cells ( Fig. 4g and Extended Data Fig. 8d) , again phenocopying the knockdown of GOF p53 itself (Extended Data  Fig. 8e ), but did not reduce the growth of either p53 null LFS cells (Fig. 4h and Extended Data Fig. 8f ), nor primary non-cancer cells with wild-type p53 (IMR90 lung fibroblasts, Extended Data Fig. 8g, h ). Reexpression of MLL1 again partially rescued the growth reduction by GOF p53 knockdown in LFS cells (Extended Data Fig. 8i ). In addition, MLL2 knockdown also decreased GOF p53 LFS cell proliferation, but not p53 null LFS cells (Extended Data Fig. 8j, k) .
COMPASS inhibitors reduce GOF p53 cell growth
Chromatin regulators have emerged as promising targets of small molecule compounds in various human diseases including cancer 11, 28 . Menin is a scaffold protein of the COMPASS complex 20 , directly interacting with the amino-terminal of MLL1 [29] [30] [31] , and is crucial for MLL1 activity and for maintenance of a subtype of leukaemia 32, 33 . We treated both GOF p53 and p53 null LFS cells with the previously reported menin antagonist, MI-2-2 (refs 34, 35). In agreement with the MLL1 genetic knockdown experiments, MI-2-2 showed a dosedependent inhibition of GOF p53 cell growth (Fig. 5a ), but had very little effect on p53 null cells (Fig. 5b) .
Recently, inhibition of MLL1 function has also been demonstrated by targeting its interaction with the WDR5 subunit of the COMPASS complex 36, 37 . As a second approach to pharmacological inhibition of MLL1 activity, we used OICR-9429, a newly characterized antagonist of interaction of WDR5 with MLL1 (ref. . In striking similarity to MI-2-2, we found a dose-dependent inhibition by OICR-9429 of GOF p53 LFS cell growth 
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G2015 Macmillan Publishers Limited. All rights reserved (Fig. 5c) , and, again, little effect on p53 null LFS cells (Fig. 5d) . Moreover, in the genetically controlled MEF cells, we observed similar results, that OICR-9429 specifically inhibits cell proliferation of GOF p53 MEFs (Fig. 5e, f) , but not when GOF p53 is reduced (Fig. 5e ) or in p53 null MEFs (Fig. 5f ). These results provide strong evidence for a specific growth inhibitory effect of pharmacological drugs in targeting MLL COMPASS complex activity downstream of GOF p53.
We examined the significance of our findings in the context of human tumour samples, by analysing The Cancer Genome Atlas (TCGA). Based on p53 mutational status, we grouped tumour samples into: (1) wild type (no detectable p53 mutation); (2) GOF (missense mutation of R175H, R248Q, R248W, R249S or R273H); or (3) p53 null (p53 nonsense mutations or frameshift truncations). Tumours with other types of p53 mutations (other missense mutations, inframe insertion/deletion, or splicing mutations) were not included in further analysis, due to an unpredictable effect on the downstream chromatin regulators. We also focused our analysis on cancer types that include more than 5% of samples in the group comprising GOF p53. We first combined all samples from these cancer types, and observed significantly higher RNA expression of MLL1, MLL2 and MOZ in GOF p53 tumours, compared to either wild-type p53 or p53 null tumours (Fig. 5g, top panels) . As controls, expression levels of housekeeping genes including actin (ACTB) and GAPDH are consistent across the three groups (Fig. 5g, middle panels) , whereas expression levels of wild-type p53 targets CDKN1A, MDM2 and PUMA are significantly higher in the wild-type p53 group than the GOF p53 or p53 null group (Fig. 5g, lower panels) . Next, we examined individual cancer types and observed similar gene expression patterns as the combination of all cancers (Extended Data Fig. 9a-f) . Notably, given the heterogeneous population of tumour samples, and the small sample size of certain groups, not all pairwise comparisons are statistically significant, although the same trends always hold that GOF p53 tumours express higher levels of MLL1, MLL2, and MOZ than the other two groups. This is also true with canonical wild-type p53 targets, that is, although not all comparisons are statistically significant, the wild-type p53 groups always show higher levels of CDKN1A, MDM2 and PUMA than the GOF p53 or p53 null tumour groups.
Discussion
Our results indicate that distinct prevalent GOF p53 mutants bind to a common newly identified group of gene targets genome-wide, to drive expression of genes comprising a chromatin signature. The GOF p53 mapping occurs immediately associated with ETS motifs, and GOF p53 binds directly to ETS2, indicating that the substitutions in the DNA-binding domain of p53 unleash a latent interaction with ETS family transcription factors, as previously suggested 8 . Within this chromatin signature gene group targeted by GOF p53, the COMPASS methyltransferase pathway appears to be particularly well represented, but the new binding includes other chromatin regulators, such as the acetyltransferase MOZ. We find that expression of these modifying enzymes is dependent on GOF p53, which in turn elevates activating histone modifications, including H3K4me3 and H3K9ac. Our evidence points to MLL downstream pathways as key targets of GOF p53. Thus, as is the case in leukaemia bearing translocations of MLL, MLL pathways may contribute to GOF p53 oncogenic phenotypes and therefore cancer progression. Importantly, our findings in both human cancer cells and LFS cells show that GOF p53 cells lose growth and tumour formation potential with similar timing kinetics upon knockdown of MLL1 as they do with knockdown of GOF p53. A key comparison-to cancer and LFS cells that express wild-type p53 or are null for p53-shows very little response to MLL1 knockdown. Hence, GOF p53 cells appear particularly dependent for growth on the MLL1 pathway. We provide further evidence of GOF p53 cell growth dependence on the COMPASS complex, by analysing cell sensitivity to two different pharmacological small compound inhibitors. These compounds target menin or WDR5 interaction with MLL1, and inhibit proliferation of LFS cells and MEFs expressing GOF p53 but not p53 null. The effects of the inhibitors are thus analogous to direct knockdown of MLL1. Hence, we conclude that a large cohort of GOF-p53-driven cancers, the growth of which was not previously known to be dependent on chromatin pathways, may be amenable to epigenetic therapeutics.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 3 and obtained from the NCI Mouse Repository. Primary MEFs from 13.5-day embryos were generated as previously described 39 , and cultured in standard tissue culture medium in a 37 uC incubator at 3% oxygen condition. Western blot and antibodies. Cells were lysed in modified RIPA buffer containing 150 mM NaCl, 1% NP-40, 50 mM Tris-Cl, pH 8.0, and 1% SDS, supplemented with protease inhibitors (Life Technologies, number 78446) before use. Protein concentration was determined by BCA protein assay (Life Technologies, number 23227), following which equal amount of proteins were loaded and separated in polyacrylamide gels. Proteins were then transferred to nitrocellulose membrane. Antibodies used in this study were as follows: p53 monoclonal antibody DO-1 (Calbiochem EMD); p53 polyclonal antibody FL393 (Santa Cruz Biotechnology, sc-6243). , number 10004D) . Following stringent washes, HA-tagged wild-type p53 or GOF p53 (generated by in vitro translation (Thermo, number 88881)) was added to co-immunoprecipitate with Flag-ETS2 in buffer containing: 20 mM Tris, pH 8.0, 137 mM NaCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 1% NP-40, and protease inhibitors. Endogenous co-immunoprecipitation experiments were performed in buffer containing: 20 mM Tris, pH 8.0, 137 mM NaCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 1% NP-40, 10% glycerol, with protease and phosphatase inhibitors, and 12.5 U ml 21 benzonase (Novagen, 70746). Bacterial expression and GST pulldown. GST-tagged ETS2 constructs were transformed and expressed in BL21-CodonPlus E. coli. Bacterial lysates were incubated with glutathione beads (Life Technologies, number G2879) at 4 uC for 2 h, and washed four times with buffer containing 50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton, 1 mM DTT, supplemented with 100 mM PMSF. The in vitro translated (Thermo, number 88881) HA-tagged wild-type p53 or GOF p53 proteins were pre-cleared with GST at 4 uC for 1 h and the resulting supernatant was subjected to GST pulldown with GST or GST-ETS2. The product was then washed and subjected to western blot analysis. RT-qPCR, ChIP-qPCR and ChIP-sequencing. RNA was isolated from cells using RNeasy kit (Qiagen, number 74106). RNA was then reverse transcribed to cDNA (Life Technologies, number 4387406), then qPCR was performed for quantification using standard procedures on a 7900HT Fast-Real-Time PCR platform (ABI). ChIP was performed as previously described 40 , with modifications. In brief, cells were crosslinked in 1% formaldehyde (Thermo, number 28906) in PBS for 10 min at room temperature. After glycine quenching, cell pellets were collected and lysed as previously described 40 , and then subjected to sonication with the Covaris sonicator (S220). The supernatant was then diluted in the same sonication buffer but without N-lauroylsarcosine, and subjected to immunoprecipitation with corresponding antibodies at 4uC overnight. The beads were then washed and DNA was reverse-crosslinked and purified. Following ChIP, DNA was quantified by qPCR using standard procedures on a 7900HT Fast-Real-Time PCR platform (ABI), or sequencing libraries were prepared using NEBNext Ultra library preparation procedure, and then sequenced on Illumina Hi-Seq platform at the NextGeneration Sequence Core at University of Pennsylvania, or on Illumina NextSeq platform in the Epigenetics Program at the University of Pennsylvania. All primer sequences used in this study are available in Supplementary Table 3 . Growth curve measurement. 200,000 cells were seeded on 950 mm 2 surface area (one well of 6-well plate) on day 0. Cell number was measured every two days with Countess automated cell counter (Life Technologies) following standard procedures and default parameter settings, after which 200,000 cells were plated back for the next count. For shRNA-mediated knockdown experiments, cells were seeded 7 days after the initial infection of shRNA-containing lentivirus, during which puromycin selection was completed and cells were returned to normal growth medium. For small compound inhibitor treatment experiments, inhibitors or DMSO vehicle control were added on day 0 as cells were seeded, and refreshed every other day as cells were counted and replated. All short hairpin sequences used in this study are available in Supplementary Table 3 . Colony-formation assay. After lentiviral infection of shRNA constructs and puromycin selection, 2,000 cells were seeded per well in 6-well plates. After three weeks, cell colonies were fixed with 1% paraformaldehyde and stained with 0.1% crystal violet (for 15 min). For quantification, the crystal violet dye was released into 10% acetic acid and measured at A 590nm (OD590). Soft agar anchorage-independent growth assay. The base layer of soft agar contained complete DMEM media (10% FBS, 100 units per ml penicillin and 100 mg per ml streptomycin) with 1% agar; the top layer of soft agar contained complete DMEM media with 0.7% agarose and was mixed with 5,000 cells and plated over the base layer. Colonies were fixed and stained with 0.005% crystal violet (for 1 h), and visible colonies were counted. Tumour xenograft assay. A total of four male and four female mice (Mus musculus, strain NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ, Jackson Labs (stock number 005557)) between the ages of 38 and 45 days old were used per treatment for tumour xenograft experiments. All animal experiments described adhere to policies and practices approved by the University of Pennsylvania Institutional Biosafety Committee (IBC) and the Institutional Animal Care and Use Committe (IACUC). Cells were collected after shRNA (MLL1 or non-targeting control) mediated knockdowns. Then 1.5 million cells were injected subcutaneously per mouse. Tumour size was measured by calipers 10 weeks after subcutaneous injection. Tumour size was measured in two dimensions, and tumour volume was calculated as 0.5 3 length 3 width 2 . All mice were euthanized 20 weeks after subcutaneous injection. Tumours were then excised and photographed. ChIP-sequencing and RNA-sequencing analysis. Human cell sequencing reads were aligned to human genome hg18 using Bowtie2 (ref. 41 ). For p53 ChIP-seq, significant regions of enrichment (peaks) were called using HOMER (Salk Institute, http://homer.salk.edu). For area under the curve analysis, ChIP-seq tags from each cell line were counted at TSS proximal peaks (200 bp around peak centres) of every cell line (including itself) as indicated. Heat maps of p53 enrichment across a 5 kb region (62.5 kb from peak centre, bin 5 10) in MCF7, MDA-MB-175VII, MDA-MB-468, HCC70, BT-549 cell lines were generated using HOMER and visualized using JavaTreeView. Sequencing reads from MEFs ChIP-seq experiments were aligned to the mouse reference genome mm9 using Bowtie2. Strand-specific mouse RNA-seq experiments were aligned to the mm9 reference genome and reference transcriptome. FPKM expression values were counted for each exon and merged into a single gene model using HOMER. Motif analysis. To determine associated sequence motifs for wild-type p53 or GOF p53 peaks, all TSS proximal peaks (filtered to remove peaks overlapping with satellite DNA) were pared down to the central 50 bp and used as input to MEME and the SeqPos utility in Cistrome (central 100 bp as required by SeqPos). MEME was instructed to search for the top 10 motifs appearing 0 or more times in each sequence, and SeqPos was run with default parameters. Gene ontology analysis. GO terms associated with wild-type p53 or GOF p53 binding sites were determined in the following way. ChIP-seq TSS proximal peaks were associated with the nearest ENSEMBL transcript and processed using DAVID. The FDR was controlled at 1% and GO terms with fewer than 5 associated transcripts or a fold-enrichment over the genomic background under fivefold were discarded. Intersection with ENCODE transcription factor data sets. Transcription factor peak coordinates (hg18 assembly) were obtained from the ENCODE project repository (http://www.encodeproject.org) in BED format. TSS proximal p53 ChIP-seq peak regions were intersected with all transcription factor binding-site data using BEDTools, with overlap inferred if a minimum of a single base pair was in common. TCGA analysis. Exome sequencing and RNA sequencing data sets were obtained from TCGA (https://tcga-data.nci.nih.gov/tcga/). Based on p53 mutational status from the exome sequencing data sets, we grouped tumour samples into: (1) wild type (tumours without detectable p53 mutation); (2) GOF (tumours with p53 single missense mutation of R175H, R248Q, R248W, R249S or R273H); and (3) null (tumours with p53 nonsense mutations or frameshift truncations). Tumours with other types of p53 mutations (other missense mutations, inframe insertion/ deletion, or splicing mutations) were not included in further analysis, due to an unpredictable effect on the downstream chromatin regulators. Cancer types that include more than 5% samples in group 2 were included for the combined analysis, in which RNA expression values were normalized to the wild-type group RESEARCH ARTICLE
